New Hope Network is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Vitamin E is Studied for Preventing Alzheimer's In People With Mild Impairment, Cornell Reports

WASHINGTON, Nov. 19 /PRNewswire/ -- Vitamin E is "valuable as a general antioxidant," improves mental function, and may be able to prevent or slow development of Alzheimer's disease, according to a Cornell University health publication.

The Food & Fitness Advisor, published by Cornell's Weill Medical College and aimed at women, reports in its November issue that "researchers are now investigating whether Vitamin E can delay or prevent AD (Alzheimer's disease) in people with mild cognitive impairment, involving minor mental deficits that sometimes represent early-stage AD."

Dr. Elisa Lottor, a California nutritionist and co-author of the book "Female and Forgetful," believes that Vitamin E is valuable as a general antioxidant, the Food & Fitness Advisor said.

"Since it's hard to get high levels through diet, she recommends 400 IU (international units) per day -- more if you have circulatory or heart problems, or a hereditary disposition to AD," the Cornell publication said.

Both laboratory and animal studies have found that Vitamin E protects brain cells from damage by free radicals, molecules that can cause the damaging body process called oxidation, it said. The studies also determined that Vitamin E can improve mental function.

"Some clinical evidence suggests that this vitamin may be able to prevent or slow development of Alzheimer's disease," the Food & Fitness Advisor said.

Metabolife Responds to Mobile, Alabama Verdict

MOBILE, Ala., Nov. 19 /PRNewswire/ -- The following is a statement by Ed Bowron, Attorney for Metabolife (Pierce, Ledyard, Latta, Wasden, and Bowron, Mobile, Alabama):

"The undisputed evidence presented to the jury showed that every single plaintiff conceded that they did not read, much less follow, instructions and warnings on the Metabolife label, including the need to consult a health care practitioner. For over 10 years, every human clinical study conducted by respected scientists has shown that these products are safe and effective when taken as directed on the Metabolife label. We intend to appeal and are confident that the verdict will be reversed."

Naturade Inc. Reports a 3.5% Sales Reduction in 3rd Quarter 2002; Quarterly Loss Significantly Reduced Versus 2001

IRVINE, Calif. -- Naturade Inc. (OTCBB:NRDC), a leading marketer of soy protein products under the brand name Naturade Total Soy(R), today reported net sales of $3,676,706 for the three months ended Sept. 30, 2002, a decrease of 3.5% over the same period in 2001 and net sales of $10,513,325 for the nine months ended Sept. 30, 2002, down 16% over the same period in 2001.

Major trends occurring in the quarter ended Sept. 30, 2002 included:

-- Initial distribution to a major warehouse club customer;

-- Decline in sales of some key mass market customers and health food distributors plus impact from the continuing U.S. economic softness since September 2001.

-- Continued use of the proceeds from the January 2002 raising of $2.5 million for operating purposes.

The company reported a significantly lower net loss of $480,558 ($0.01 per share) for the third quarter compared with a $890,967 loss ($0.11 per share) in the third quarter of 2001. The net loss of $1,806,667 ($0.04 per share) for the first nine months of 2002 is 20% below the loss of $2,270,442 ($0.30 per share) experienced for the first nine months of 2001.

The decline in quarterly net loss reflects a significant reduction in interest expense due to a previously reported financial restructuring in January 2002, an increase in gross margin and significantly lower selling and general and administrative expenses.

According to Naturade CEO Bill Stewart: "We made good progress during the third quarter. We gained new distribution in a major warehouse club chain and launched two new brands, Quick Fizz(TM) and Power Shake(TM) to drive extra second half volume. We also began shipping new Naturade Total Soy formulations with revised label graphics that position the brand for weight loss as well as heart health. We've already seen indications that the new labels will be a strong stimulus to increased sales.

"Our focus on directly aligning promotional costs with proven sales opportunities is paying off," Stewart continued. "In the third quarter, we were able to reduce brand expenses for trade and consumer promotion by almost $200,000 to 19.2% of net sales while actually increasing sales of Naturade Total Soy with most of our mass market customers. Other reductions in interest expense and warehouse costs resulted in a 46% reduction in our third quarter net loss."

Overall mass market growth for the quarter was 0.5%. Sales to health food accounts declined 7% in the third quarter. The health food channel accounted for 48% of net sales in third quarter and 53% of net sales for the first nine months of 2002.

Non-cash accounting recognition of a $52,445 expense for preferred stock dividends resulted in a net loss attributable to common shareholders for the third quarter of $533,003. Dividends on the company's Series B Redeemable Convertible Preferred Stock accrue at an annual rate of 10% and accumulate if unpaid.

With headquarters in Irvine, Naturade -- since 1926 -- has been committed to marketing innovative natural products to improve the health and well being of consumers. Well known for its 50 years of leadership in soy protein, Naturade is the number one brand name of natural soy protein powders sold in food, drug and mass merchandise stores.

Its premier product, Naturade Total Soy, is a complete line of ready-to-drink, bars and shake mix meal replacement products sold at major supermarkets and drug, health food, club and mass merchandise stores throughout the United States. The company's other brands include Power Shake(R), Quick Fizz(TM) and Aloe Vera 80(R). For more information, visit www.naturade.com.

Note: The private securities litigation reform act of 1995 provides a "safe harbor" for certain forward-looking statements. The statements contained in this news release that are not historical facts are forward-looking statements based on the company's current expectations and beliefs concerning future developments and their potential effects on the company, including, without limitation, statements concerning the company's strategies and initiatives to improve business results. There can be no assurance that future developments affecting the company will be those anticipated by the company. Actual results may differ from those projected in the forward-looking statements. These forward-looking statements involve significant risks and uncertainties (some of which are beyond the control of the company) and are subject to change based upon various factors. These factors include the impact of government regulations, less stable demand in the mass market, the decline of the health food sector, the company's ability to secure new mass market customers, the company's ability to convert new distribution to repeat sales, the company's ability to effectively continue to reduce brand expenses, variability of quarterly earnings, business interruption due to terrorism, ability to continue as a going concern and potential future earnings losses, dependence on key customers, dependence on current and ongoing financing, dilution due to future equity sales, technological changes, dependence on third-party manufacturers, pricing pressures and other competitive factors, dependence on qualified personnel, product liability exposure, inability to identify strategic growth partners, instability of the dietary supplement industry, impact of adverse publicity, limited success of new products, insufficient protection of intellectual property, stock price volatility and close control of company stock. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. For a more detailed discussion of some of the ongoing risks and uncertainties of the company's business, see the company's filings with the Securities and Exchange Commission.

CONSOLIDATED STATEMENTS OF INCOME

Three Months Ended (unaudited) 9/30/02 9/30/01

Net Sales $3,676,706 $3,811,001
Gross Profit $1,666,198 $1,705,443
Gross Margin % 45.3% 44.8%
Net Loss ($480,558) ($890,767)
Net Loss applicable to common shares ($533,003) ($890,767)
Net Loss per common share ($0.01) ($0.11)
Weighted average common shares outstanding 44,236,333 7,823,639


CONDENSED CONSOLIDATED BALANCE SHEET

Sept. 30, 2002 Dec. 31, 2001 (unaudited) (audited)

Current assets $ 2,847,093 $ 3,631,370
Property and equipment, net 248,723 307,362
Other assets 78,594 54,763
Total assets $ 3,174,410 $ 3,993,495

Current liabilities $ 4,237,719 $ 5,495,486
Long-term debt, less current maturities 45,374 5,507,382
Redeemable convertible preferred stock & warrant 2,415,657
Stockholders' deficit (3,524,340) (7,009,373)
Total liabilities and shareholders' deficit $ 3,174,410 $ 3,993,495

CONTACT:
Naturade Inc.,
John Hazlin,
714/573-4800 ext. 221

Organic Essentials Introduces Disposable Nursing Pads made with 100% Certified Organic Cotton

New Moms Can Take Comfort in Organic Protection
From Organic Essentials!

O’Donnell, Texas -- Organic Essentials, Inc. announces the introduction of their new Disposable Nursing Pads made with 100% certified organic cotton. Packaged in handy, reusable, drawstring carrying bags, the nursing pads have a breathable, hypoallergenic outer shell that provides comfortable protection against leaks and stains while the extra-absorbent organic cotton lining draws moisture away from the skin. “Not only will nursing moms feel safe and protected wearing these pads but they will have the satisfaction of using a product that was grown sustainably on U.S. family farms,” says La Rhea Pepper, one of the founders of Organic Essentials and its current President.

The statistics in the production of conventional cotton in the world indicate a shift is clearly warranted for the protection of our ecosystems. According to the Sustainable Cotton Project and Pesticide Action Network of North America, cotton uses about 28 percent of the world’s insecticides and more than 10 percent of all pesticides. In the U.S., cotton ranks #3 in crops with the heaviest pesticide use. Through customer feedback, Organic Essentials has seen an increasing number of consumers showing sensitivities to the synthetic chemicals, pesticides, fungicides, fertilizers and defoliants used on cotton. La Rhea adds, “To use organic cotton products is the only responsible choice for the health of families and the health of the planet.”

Organic Essentials has been manufacturing high quality, certified organic personal care items such as tampons, cotton swabs and cotton balls since 1996. Founded and owned by the Texas Organic Cotton Marketing Coop (TOCMC), Organic Essentials and its sister business, Cotton Plus, hold firm their vision to supply chemical-free personal care products and certified organic cotton fabric to consumers everywhere.

Organic Cotton You Can Trust!

##########

La Rhea Pepper can be reached at 800.765.6491.

American Oriental Bioengineering Announces Acquisition Of Soybean Protein Peptide Operation

American Oriental Bioengineering Announces Acquisition Of Soybean Protein Peptide Operation

HARBIN, China, -- American Oriental Bioengineering, Inc. (OTC Bulletin Board: AOBO - News), a leading producer and developer of bioengineered products and Chinese medicine in China, today announced it has acquired a 100% ownership stake in a large capacity soybean peptide manufacturing plant, the exclusive rights to market and sell several medically functional soybean peptide products and the ownership rights to a Chinese patent-pending process for the extraction and production of soybean peptides (the "Protein Peptide Project").

The Company will obtain ownership of the Protein Peptide Project in exchange for issuing 20,284,810 shares of Common Stock and 1,000,000 shares of Class A Preferred Stock. The value of the Common Stock to be issued is $3,205,000, or $0.158 per share, which represents the average closing price of the Company's stock for the five-day period from August 19 to August 23, 2002. The Company has filed a Schedule 14C Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934. The date of closing is expected be in 20 calendar days following the filing of the 14C.

The acquisition will increase the issued and outstanding equity of the Company to 30,425,827 shares of Common Stock and 1,000,000 shares of Preferred Stock. The issuance shall be made approximately 20 calendar days after the 14C is filed with the Securities and Exchange Commission and mailed to the shareholders of the Company.

The assets being acquired were developed by Shujun (Tony) Liu, the Company's President, under a separate development program which employed a team of more than twenty biochemists and biologists working in conjunction with Harbin Medical University in Harbin City, within the Heilongjiang Province in the People's Republic of China. The assets being acquired include a soybean peptide manufacturing plant with an annual capacity of 1,000 tons of product, the exclusive marketing and sales rights to several functional soybean protein peptide medical tablets and powder-based products, and full ownership rights on a Chinese patented process for a more efficient extraction and production of soybean peptides.

Soybean peptides are traditionally derived from soybeans through biochemical engineering processes which include the cutting, decomposition, conversion and synthesis of soybean protein. Soybean peptide production yield distinct enzymes that have diverse biological functions and combine the nutrition of soybean protein with important biological benefits. Experiments have shown that the soybean peptide can lower blood pressure and blood fat levels, enhance immunity, lower cholesterol, prevent cardiac and brain blood vessel diseases and inhibit the growth of tumors.

Soybean Peptides can be used widely in general food and health food products, sports foods, medicines, the fermentation industry and in environmental protection applications. All soybean peptides have been shown to be easily absorbed by the body, and can also be used as an additive in various foods and beverages including milk, tea and coffee.

Tony Liu, President of AOBO, made the following comments concerning the Company's operations: "We are very pleased with the potential revenue opportunities presented by our recently completed acquisition. This acquisition will support our recent progress in developing and test marketing additional nutritional products for Asia's large and growing health products markets. We are well-positioned to take advantage of the increased demand for traditional Chinese medicine, as well as the significant opportunities presented for marketing our newly developed bioengineered products internationally. Additionally, as we recently announced, we are working to build foreign distribution agreements in order to commence sales in the U.S and Europe."

About American Oriental Bioengineering, Inc.

American Oriental Bioengineering, Inc., formally know as Harbin Three-Happiness Bioengineering Co., Ltd. was founded in 1994. The Company has become a leading producer and developer of bioengineered products and Chinese medicine in China, and utilizes proprietary processes that give it advantages in the manufacture and formulation of some of its products. The Company is engaged in the development and production of nutritional products and Chinese medicine, and has proprietary processes that give it advantages in the manufacture and formulation of some of its products. Important relationships with Harbin University of Medical Sciences, the Ocean Research Institute of China Academy of Sciences and the Shenyang Ecological Research Institute of China Academy of Sciences support the creation of an evolving pipeline of new and improved products. The Company has a total of 150 employees, of which 70 are involved in sales and marketing and 20 are dedicated to research.

Safe Harbor Statement

Except for the historical statements made herein, the statements made in this release are forward-looking statements, including: "We are well-positioned to take advantage of the increased demand for traditional Chinese medicine, as well as the significant opportunities presented for marketing our newly developed bioengineered products internationally" and "we are working to build foreign distribution agreements in order to commence sales in the U.S and Europe." Risk factors that could cause actual results to differ materially from those projected in forward-looking statements include, but are not limited to, general business conditions, managing growth, and political and other business risks. Although the Company believes that the forward-looking statements contained herein are reasonable, it can give no assurance that the Company's expectations are correct. All forward-looking statements are expressly qualified in their entirety by this Cautionary Statement and the risks and other factors detailed in the Company's reports filed with the Securities and Exchange Commission.

Investor Contact:
Harvey Goralnick/David Zazoff
FOCUS Partners LLC
212-752-9445
[email protected]

CRN Questions Conclusion of Wave Study

-Reminds Consumers of Scientific Basis for Safety and Benefits of Vitamins E and C-

WASHINGTON, D.C., The Council for Responsible Nutrition (CRN), one of the dietary supplement industry’s leading trade associations, today responded to the conclusions drawn by the authors of the Women’s Angiographic Vitamin and Estrogen (WAVE) Trial study as being “an exaggerated recommendation based on inconclusive data.”

CRN noted that careful analysis of the study reveals the study showed no effects beyond random variations in response and that the researchers based their conclusions on statistically insignificant data. “In fact, the actual data showed no difference in artery blockage between the antioxidant group and the control group, even after the researchers arbitrarily created ‘worst-case’ numerical values to fill missing data points,” stated John Hathcock, Ph.D., vice president, nutritional and regulatory science, CRN. “Even those statistics that would appear to be significant are, in actuality, the exact pattern that would randomly occur if no treatments had been administered, and as the authors have stated, this could be a ‘chance finding.’”

Further scrutiny exposes flaws in the study’s design. For example, the study groups were not stratified to assure that all the treatment groups were similar with respect to the degree of coronary artery blockage. In addition, the authors concede that their study was powered only to detect the degree of blockage of the arteries, not the differences in clinical outcomes. Yet much of their discussion focuses on comparisons of clinical outcomes.

The authors of the WAVE study asserted that the results of the Heart Protection Study (HPS) provided support to their conclusions by identifying “a trend toward an increase in mortality” in the vitamin group. However, the authors of the HPS actually reported “no significant differences” in mortality. (Lancet 2002; 360:23-33.)

Dr. Hathcock noted that there is broad scientific consensus that dietary supplements of vitamins E and C are safe in the general population. “It is the cumulative knowledge, or the weight of the overall evidence, that provides health care professionals and consumers with the best scientific guidance. Over the past 25 years, more than 20 studies involving more than 80,000 people have been conducted on vitamins E and C, and on balance these are overwhelmingly safe nutrients.”

The WAVE study should not be considered “the final word,” said Dr. Hathcock who pointed out that another secondary prevention trial of antioxidant vitamins and cardiovascular disease (CVD) in women has been going on for over seven years. The Women’s Antioxidant and Cardiovascular Study (WACS), being conducted by Harvard Medical School and funded by the National Heart, Lung and Blood Institute, involves a larger, but similar, study population to WAVE. The randomized, double-blind, placebo-controlled trial is studying the balance of benefits and risks of vitamins E and C, and beta-carotene, among 8000 women with preexisting CVD.

The Institute of Medicine (IOM) recently established Tolerable Upper Intake Levels (UL) for daily intake for vitamin E and vitamin C, based on an exhaustive review of the medical scientific literature, and set upper safe levels at 1000 mg for vitamin E and 2000 mg for vitamin C.

Vitamins E and C are essential nutrients required for maintenance of health. Vitamin E has potential benefits for vision, Alzheimer’s disease, counteracting free radicals that may play a role in fighting cancers, and reducing the risk of coronary disease. Vitamin C is believed to promote a healthy immune system and may also be beneficial in preventing free radical damage potentially leading to diseases such as cancer.

According to statistics from a 2001 Gallup Study, over 100 million American adults annually take vitamins E and C in dietary supplement form, either in single nutrient supplements or in multivitamins.

Seventh LOHAS Market Trends Conference to Focus on Aging Boomers

New Consumers in the $230-billion “Lifestyles of Health and Sustainability” Market

CEO-level business conference to focus on branding, consumer trends, growth factors and investment in the market for natural, organic, sustainable and socially responsible products

BROOMFIELD, Colo. – How will an aging population, the environment, politics and an increased need for self-sufficiency affect the markets for natural and organic products, alternative transportation, renewable energy, green building and other sustainable products and services? Recognized business and thought leaders will explore these and other issues affecting investment and growth in the $230-billion “Lifestyles of Health and Sustainability” or LOHAS market at the 7th LOHAS Market Trends Conference and Trade Fair, June 18-20, 2003, at the Omni Interlocken Resort in Broomfield, Colo.

This year's premier business event integrating the markets for natural, organic, sustainable and socially responsible products and services will draw 500 executives, business owners, marketers and investors who will convene to network, share ideas and resources, exhibit products and hear leading speakers who are helping to drive double-digit growth in this rapidly growing market.

Confirmed keynote speakers for the event include Ken Dychtwald, Ph.D., and Paul H. Ray, Ph.D. Dychtwald has emerged as the nation's leading authority on the mature market. He is a psychologist, demographer, futurist and author of 10 books, including his best selling Age Wave and his newest book, Age Power: How the 21st Century Will be Ruled by the New Old. Dychtwald's accurate predictions about the aging of America have been featured on CBS News and in publications including Fortune, TIME, Newsweek, Business Week, USA Today, Wall Street Journal, and Advertising Age. Ray, author of The Cultural Creatives: How 50 Million People Are Changing the World, will present key consumer research and information on how LOHAS companies can successfully navigate the current economic, political and sociological landscape.

In addition, the program will feature keynotes, breakouts, roundtables, intensive workshops, an exhibit hall, and special meetings and events featuring top LOHAS industry leaders. Presentations will focus on branding strategies, growth trends, investment opportunities, sustainable business practices and how to market to Cultural Creatives—a values-based, health and environmentally conscious consumer movement comprised of 63 million U.S. adults, or 30% of all U.S. households.*

“LOHAS-oriented businesses have the opportunity to profit and change the world for the better at the same time. This conference serves as the leading forum to showcase LOHAS products and in bringing together top business leaders who serve a common, value-based consumer,” says event director Steven Hoffman. “The conference is critical in helping to integrate diverse businesses dedicated to health, sustainability and social responsibility, to foster increased communication and collaboration among them, and to inspire them to compete and succeed in the greater marketplace.”

The Omni Interlocken Resort in Broomfield, Colo., is located between Denver and Boulder, approximately 45 minutes from Denver International Airport. Colorado's Front Range is a center of natural and sustainable products and other LOHAS-related business activity.

The 7th LOHAS Market Trends Conference and Trade Fair is produced by Broomfield, Colo.-based Conscious Media Inc., publisher of LOHAS Journal, the leading business publication serving the health and sustainability market. For information on exhibiting, sponsorship, or registration, or for information on LOHAS Journal and market research, contact Conscious Media Inc., Tel 303.442.8983, email [email protected], or visit www.LohasJournal.com.

* Based on a recent Harris Interactive survey of 2,267 households, Understanding the LOHAS Market, produced by Natural Business Communications, a division of Conscious Media Inc., and Natural Marketing Institute, copyright May 2002. For information visit www.LohasJournal.com.

New Research Suggests Potential Link Between Eating Flavanol-Rich Chocolate and Improved Blood Vessel Function

Findings Presented at American Heart Association Scientific Sessions Provide Further Indications that Certain Chocolates May Support Heart Health

CHICAGO, Nov. 20 /PRNewswire/ -- New research presented today during one of eleven special sessions sponsored by the Scientific Councils of the American Heart Association suggests a potential link between cocoa flavanols contained in certain chocolates and improved blood vessel function. Blood vessel function is believed to be an important indicator of cardiovascular health, much like cholesterol levels or blood pressure.

Reported at a session entitled "Chocolate and Wine for the Heart? The Science Behind Dietary Flavanols and Cardiovascular Health," the new research reinforces previous research results suggesting that cardiovascular health may be positively affected by intake of naturally occurring dietary flavanols in certain chocolates and cocoas. The independently funded study, presented by co-investigator Marguerite M. Engler, Ph.D., R.N., M.S., F.A.H.A., professor and vice chair of the Department of Physiological Nursing, University of California at San Francisco, compared the effects of consuming a commercially available flavanol-rich dark chocolate bar (DOVE(R) Dark Chocolate, Mars, Incorporated) to the effects of consuming a flavanol-poor dark chocolate product on blood vessel function.

Twenty-one healthy subjects consumed 46 grams of either the flavanol-rich (259 mg of chocolate flavanols) or a flavanol-poor chocolate product each day for two weeks in the randomized, double-blind, placebo-controlled clinical study. Researchers measured the level of flavanols in participants' blood, and found that the chocolate flavanols in the flavanol-rich chocolate were absorbed into the blood stream. Flow-mediated dilation was also examined as an indicator of endothelial function, using ultrasound (sound waves) to image a blood vessel in the arm called the brachial artery. The endothelium is the inner lining of blood vessels responsible for regulating blood vessel dilation, or relaxation. Flow-mediated dilation is a measure of blood vessel dilation or elasticity in response to an increase in blood flow. Principle investigator, Mary B. Engler, Ph.D., R.N., M.S., F.A.H.A., professor of the Department of Physiological Nursing, University of California at San Francisco, and her research team found that the participants who consumed the flavanol-rich DOVE(R) Dark chocolate product exhibited blood vessel dilation two hours after chocolate consumption, compared to test results at baseline.

"The exciting news here is that blood vessel dilation increased in subjects who ate this commercially available chocolate product," said Dr. Marguerite Engler. "This is consistent with previous research suggesting that certain chocolates do contain enough flavanols to support cardiovascular health."

Flavanols are a sub-class of flavonoids found naturally in a variety of plant-based foods, including certain cocoas, chocolates and red wine. Decades of studies suggest that flavanols may have a host of potentially beneficial health effects. The University of California, San Francisco study supports previous research suggesting that chocolate flavanols may positively affect cardiovascular health in a number of ways. For example, studies suggest that:

* Consumption of flavanols may have an effect on the relaxation of the
smooth muscle surrounding blood vessels, an effect called vascular
dilation. Vascular dilation is important to maintaining healthy blood
flow through the vessels and is believed to be an important indicator
of cardiovascular health.
* Early in vitro research suggests that chocolate flavanols may enhance
nitric oxide synthesis and/or maintain its availability for action
within blood vessels. These and other studies have suggested the
important role that nitric oxide plays in the maintenance of a healthy
cardiovascular system by dilating arteries to increase blood flow,
maintaining elasticity and preventing platelets from adhering to artery
walls. The results of this new human study suggest that consumption of
chocolate flavanols may have the same action in vivo, since consumption
of the flavanol-rich cocoa increased flow-mediated dilation in
subjects.
* Consumption of flavanols may have an aspirin-like effect on blood
components called platelets, which play a significant role in blood
clotting. Decreasing platelet activity is thought to be supportive of
heart health.

"As health professionals, we are very excited to find that a food consumers can enjoy eating in moderation may have measurable benefits on health," said Carl L. Keen, Ph.D., professor and chair, Department of Nutrition, professor, Department of Internal Medicine, University of California at Davis, who also presented research at the session. "We've hypothesized that chocolate, if processed properly, could contain enough flavanols to have a beneficial effect on heart health. The study from University of California, San Francisco further reinforces this hypothesis."

Before consumers reach for that chocolate bar, it's important to know that not all chocolate retains the naturally-occurring flavanols, because these compounds can be lost during processing of the cocoa. Mars, Incorporated has developed proprietary methods of processing cocoa beans to retain much of the naturally-occurring flavanols in their chocolate products. The company marks these products with the Cocoapro(TM) logo, a symbol of a hand holding a cocoa bean, to signify the careful handling of the cocoa bean.

As one of the world's leading producers of chocolate, Mars, Incorporated has a strong commitment to chocolate and health research and produces a wide variety of quality snackfoods, including "M&M's"(R) Chocolate Candies, DOVE(R) Chocolate, SNICKERS(R), and 3MUSKETEERS(R) Bars.


Cargill Health & Food Technologies Launches AdvantaSoy™ Isoflavone For Dietary Supplement Use AdvantaSoy™ Compress™ makes variable isoflavone concentration easy

MINNEAPOLIS - Cargill Health & Food Technologies (H&FT) is introducing AdvantaSoy™ Compress™-- a soy isoflavone ingredient that was developed specifically for the dietary supplement industry. Cargill H&FT can customize AdvantaSoy™ Compress™ and can generate concentrations up to 50 percent.

“AdvantaSoy™ Compress™ is designed to better serve the dietary supplement industry,” said Lee Knudson, product manager for Cargill Health & Food Technologies. “Our product is produced using the same proprietary technology that made AdvantaSoy™ Clear™ a success. AdvantaSoy™ Compress™ is a premium soy isoflavone source available in variable concentrations,” he said.

The demand for natural women's health products has increased dramatically in recent years. Preliminary data in the published scientific literature suggests that isoflavones may benefit health by relieving some menopausal symptoms and maintaining bone health. Additional research is underway on a number of areas, specifically bone health.

“There is burgeoning research underway investigating the effect of various isoflavones on maintaining bone mass,” said Dr. D. Lee Alekel, associate professor of nutrition at Iowa State University. “With the findings from each new study we move a step closer to understanding the potential of isoflavones in health and disease prevention,” Dr. Alekel said.

Cargill Health & Food Technologies, based in Minneapolis, is a leading developer, processor and marketer of science-based, healthy ingredients for food and dietary supplements worldwide. HFT is part of Cargill's Food System Design initiative in which Cargill businesses work with customers to produce ingredient solutions for affordable, nutritious, convenient and appetizing consumer products. HFT is a business unit of Cargill, Incorporated, an international marketer, processor and distributor of agricultural, food, financial and industrial products and services with 97,000 employees in 59 countries. The company provides distinctive customer solutions in supply chain management, food applications, and health and nutrition.

CRN Applaunds AHA Recomendation On The Benefits of Omega-3 Fatty Acids

WASHINGTON, D.C., - The Council for Responsible Nutrition (CRN), one of the dietary supplement industry's leading trade associations, today commended the American Heart Association (AHA) for urging people to consume omega-3 fatty acids to protect their hearts. According to Annette Dickinson, Ph.D., vice president, scientific and regulatory affairs, CRN, the good news from AHA and the accompanying recommendations published in the Nov. 18 issue of Circulation: Journal of the American Heart Association "recognize the importance of omega-3 fatty acids in a healthy diet and the science that supports these valuable nutrients."

The report recommended that healthy adults eat at least two servings of fish per week, particularly those containing the most potent form of omega-3 fatty acids, EPA (eicosapentaenoic) and DHA (docosahexaenoic). In addition, the report pointed out that some people need more EPA and DHA than can be readily achieved through diet alone, and in those cases, omega-3 fatty acid supplements should be considered. AHA states that people with coronary artery disease "in consultation with their physician, should consider supplements for CHD risk reduction."

"Americans, in particular, do not eat enough fish and we agree with the American Heart Association that it would make good sense for healthy adults to eat two servings a week of the right kinds of fish. For those people who are not getting enough omega-3 fatty acids from their diet, omega-3 supplements are a convenient and affordable option," stated Dr. Dickinson.

CRN's Omega-3 Working Group recently issued a voluntary monograph intended to raise the bar for the quality of long chain Omega-3 EPA and DHA products marketed in North America, in order to ensure greater consumer confidence in these beneficial nutrients. For more information, visit http://www.crnusa.org/Shellnr111902B.html

The Council for Responsible Nutrition (CRN) is one of the dietary supplement industry's leading trade associations representing ingredient suppliers and manufacturers. CRN members adhere to a strong code of ethics, comply with dosage limits and manufacture dietary supplements to high quality standards under good manufacturing practices.